Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.

Abstract

BACKGROUND:

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease impacting an estimated 44 million adults worldwide. The causal pathology of AD (accumulation of amyloid-beta and tau), precedes hallmark symptoms of dementia by more than a decade, necessitating development of early diagnostic markers of disease onset, particularly for new drugs that aim to modify disease processes. To evaluate differentially methylated positions (DMPs) as novel blood-based biomarkers of AD, we used a subset of 653 individuals with peripheral blood (PB) samples in the Alzheimer's disease Neuroimaging Initiative (ADNI) consortium. The selected cohort of AD, mild cognitive impairment (MCI), and age-matched healthy controls (CN) all had imaging, genetics, transcriptomics, cerebrospinal protein markers, and comprehensive clinical records, providing a rich resource of concurrent multi-omics and phenotypic information on a well-phenotyped subset of ADNI participants.

RESULTS:

In this manuscript, we report cross-diagnosis differential peripheral DNA methylation in a cohort of AD, MCI, and age-matched CN individuals with longitudinal DNA methylation measurements. Epigenome-wide association studies (EWAS) were performed using a mixed model with repeated measures over time with a P value cutoff of 1 × 10-5 to test contrasts of pairwise differential peripheral methylation in AD vs CN, AD vs MCI, and MCI vs CN. The most highly significant differentially methylated loci also tracked with Mini Mental State Examination (MMSE) scores. Differentially methylated loci were enriched near brain and neurodegeneration-related genes (e.g., BDNF, BIN1, APOC1) validated using the genotype tissue expression project portal (GTex).

CONCLUSIONS:

Our work shows that peripheral differential methylation between age-matched subjects with AD relative to healthy controls will provide opportunities to further investigate and validate differential methylation as a surrogate of disease. Given the inaccessibility of brain tissue, the PB-associated methylation marks may help identify the stage of disease and progression phenotype, information that would be central to bringing forward successful drugs for AD.

• Authors: Aparna Vasanthakumar, Justin W Davis, Kenneth Idler, Jeffrey F Waring, Elizabeth Asque, Bridget Riley-Gillis, Shaun Grosskurth, Gyan Srivastava, Sungeun Kim, Kwangsik Nho, Kelly N H Nudelman, Kelley Faber, Yu Sun, Tatiana M Foroud, Karol Estrada, Liana G Apostolova, Qingqin S Li, Andrew J Saykin, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
• Journal: Clinical epigenetics (Clin Epigenetics) Vol. 12 Issue 1 Pg. 84 (06 15 2020) ISSN: 1868-7083 [Electronic] Germany
• PMID: 32539856 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Biomarkers

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (blood, cerebrospinal fluid, diagnostic imaging)
• Biomarkers (blood, cerebrospinal fluid)
• Case-Control Studies
• Cognitive Dysfunction (blood, cerebrospinal fluid, diagnostic imaging)
• DNA Methylation (genetics)
• Diagnosis, Differential
• Disease Progression
• Early Diagnosis
• Epigenomics (methods)
• Female
• Genotype
• Humans
• Longitudinal Studies
• Male
• Mental Status and Dementia Tests (standards)
• Neuroimaging (methods)
• Phenotype
• Transcriptome (genetics)